Expanding access to investigational new therapies
- PMID: 1594704
Expanding access to investigational new therapies
Abstract
One important role for the primary care provider is to be familiar with all available treatment options for HIV disease. Because only a few treatments are approved, unapproved therapy becomes important for many patients. As a result, clinicians have had systems developed that create access to promising investigational drugs. In addition, because of the urgent need to increase the number of proven treatments, some clinicians have chosen to become more directly involved in the evaluation of new treatments for HIV disease by becoming community based "clinician-researchers."
Similar articles
-
FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.Food Drug Law J. 2009;64(1):183-223. Food Drug Law J. 2009. PMID: 19998746
-
Expanded access to investigational drugs for treatment use. Final rule.Fed Regist. 2009 Aug 13;74(155):40900-45. Fed Regist. 2009. PMID: 19691173
-
Individual patient treatment use of unapproved drugs: a new option for the seriously ill.J Pain Palliat Care Pharmacother. 2010 Mar;24(1):19-22. doi: 10.3109/15360280903583057. J Pain Palliat Care Pharmacother. 2010. PMID: 20345195
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Research as a path to wide-scale implementation of antiretroviral therapy in Africa.J HIV Ther. 2004 Sep;9(3):65-8. J HIV Ther. 2004. PMID: 15534564 Review.
Cited by
-
The interplay between HIV and COVID-19: summary of the data and responses to date.Curr Opin HIV AIDS. 2021 Jan;16(1):63-73. doi: 10.1097/COH.0000000000000659. Curr Opin HIV AIDS. 2021. PMID: 33186229 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials